Sign In
Buy XCUR
$2.73
-0.0100 (-0.365%)
At Close: Jun 23, 2026
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
04:15pm, Wednesday, 22'nd Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to sha
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
07:00am, Monday, 06'th Oct 2025
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Developm
Exicure Posts Wider Loss in Fiscal Q2
04:19pm, Friday, 08'th Aug 2025
Exicure Posts Wider Loss in Fiscal Q2
Exicure, Inc. Reports Second Quarter 2025 Financial Results
04:01pm, Friday, 08'th Aug 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
04:37pm, Monday, 04'th Aug 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.
Exicure, Inc. Reports First Quarter 2025 Financial Results
04:01pm, Friday, 27'th Jun 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Q1 2025 earnings release.
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
04:58pm, Wednesday, 28'th May 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant.
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
06:11pm, Monday, 14'th Apr 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma.
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
07:42pm, Friday, 11'th Apr 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
04:08pm, Thursday, 13'th Mar 2025
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Issuance of New Patent in Australia.
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
12:17am, Thursday, 23'rd Jan 2025
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
04:01pm, Wednesday, 22'nd Jan 2025
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
08:08pm, Thursday, 26'th Dec 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Partners with GPCR Therapeutics Inc. to Fuel New Growth in Biotech.
